FindTrial
Sign In

Efficacy and Safety of Elbasvir/Grazoprevir Treatment in Chinese Patients with Hepatitis C Virus Genotype 1b: A Retrospective Study

Efficacy and Safety of Elbasvir/Grazoprevir Treatment in Chinese Patients with Hepatitis C Virus Genotype 1b: A Retrospective Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032528
Enrollment
Unknown
Registered
2020-05-01
Start date
2018-08-01
Completion date
Unknown
Last updated
2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Viral hepatitis c

Interventions

Case series:Elbavegravir was administered orally, one tablet at a time, once a day, for 12 weeks

Sponsors

The Second Affiliated Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
23 Years to 76 Years

Inclusion criteria

Inclusion criteria: 1. aged > 18 years old; 2. the serum HCV-RNA of the patients was higher than 15 IU/ml detected by COBAS TaqMan; 3. patients with hcv-1b; 4. child-pugh score is grade A.

Exclusion criteria

Exclusion criteria: 1. treated hcv-1b patients; 2. patients with inevitable drug-drug interactions (DDI) in the initial treatment of hcv-1b with complications; 3. initial treatment of hcv-1b patients with tumor.

Design outcomes

Primary

MeasureTime frame
HCV-RNA;—

Countries

China

Contacts

Public ContactZhang Liyi

The Second Affiliated Hospital of Lanzhou University

zhanglymd@126.com+86 15193100697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026